B 27PD
Alternative Names: B27PD; Optiquel; OptiquelTLatest Information Update: 04 Nov 2017
At a glance
- Originator Ludwig-Maximilians-University
- Developer Enzo Biochem; Ludwig-Maximilians-University; National Eye Institute
- Class Anti-inflammatories; Eye disorder therapies; Peptides
- Mechanism of Action HLA antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Uveitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Uveitis in Germany (PO, Capsule)
- 23 Sep 2015 Phase-I/II development is ongoing for Uveitis
- 01 Aug 2010 Phase-I/II clinical trials in Uveitis in USA (PO)